The aim of the current study is to evaluate the efficacy and safety of high dose oral NAC
(2400 mg/day divided into two doses) as an adjunct therapy on oxidative stress, inflammatory
markers and clinical outcome in patients with type 2 diabetes suffering from diabetic
peripheral neuropathy.